Medisix Therapeutics is a provider of immune engineering company developing novel cellular therapies.
Medisix Therapeutics is a Singapore-based immune engineering company developing novel cellular therapies to address T cell malignancies. Their technology platform originates from world expert in translational immunology, Professor Dario Campana, MD, PhD, a physician scientist who pioneered chimeric antigen receptor T cell (CAR-T) biology. Their programs utilize proprietary immune engineering approaches that enable T cell leukemias and lymphomas to be targeted with cell therapy.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
May 15, 2018 | Series A | $20M | 3 | Lightstone Ventures | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Lightstone Ventures | Yes | Series A |
OUP (Osage University Partners) | — | Series A |
Temasek Holdings | — | Series A |